Professor Wang Jianxun, Chief Scientist of Shenzhen Cell Valley Biopharmaceutical Co., Ltd., together with Sun Rui, Head of Marketing, visited Shenzhen Second People's Hospital (the First Affiliated Hospital of Shenzhen University). They held in-depth discussions with Professor Nie Guohui, Director Chen Yingqi of the Medical Innovation Technology Translation Center, and the hospital's core research team. The two sides engaged in extensive talks covering policy interpretation, platform advantages, clinical translation, and strategic cooperation, jointly charting a blueprint for the development of Shenzhen's cell therapy industry.

During the exchange, the Shenzhen Cell Valley team detailed the group's core industrial strengths and offered an in-depth interpretation of current national biomedical policies, with particular emphasis on the company's commitment to aligning with national strategic directions in building a one-stop translation platform for emerging biomedical technologies. Decree No. 818, as the first special regulation in China's biomedical field, establishes a full-chain regulatory framework for cutting-edge technologies such as cell therapy, marking the industry's entry into a new era of standardized, high-quality development.

Professor Wang Jianxun noted that Cell Valley has consistently adhered to national strategic guidance, deeply cultivating the cell and gene therapy (CGT) sector. Leveraging its core industrial-scale retroviral vector technology, the company has broken down barriers across the entire industrial chain—from R&D and manufacturing to clinical translation—providing compliant, efficient, and stable industrial support for hospitals and research institutions. Professor Nie Guohui strongly concurred, emphasizing that Shenzhen Second People's Hospital will strictly follow policy requirements and actively embrace cutting-edge technologies such as cell therapy to deliver more precise and effective treatment options for patients.

As a major public service platform for biomedicine in Shenzhen, Shenzhen Cell Valley boasts a world-class R&D team and a GMPcompliant production system. It is the first enterprise in China capable of industrial-scale production of viral vectors. The platform offers end-to-end services spanning technology R&D, pilot scale-up, quality control, and regulatory filing for emerging clinical technologies. It has accumulated extensive industrial experience particularly in immune cell therapies such as CAR-T and CAR-NK. Director Chen Yingqi expressed strong appreciation for Cell Valley's technical capabilities and platform strengths. He noted that the Medical Innovation Technology Translation Center at Shenzhen Second People's Hospital is dedicated to building a closed loop of translation—from clinical problem identification and research breakthrough to concept validation and pilot production—and urgently needs deep collaboration with an industry leader like Cell Valley. Such a partnership would seamlessly integrate the hospital's abundant clinical resources and patient samples with the company's technology, production capacity, and industrialization expertise, thereby solving the "last mile" challenge in clinical R&D.

The two sides conducted substantive discussions on clinical technology translation and cutting-edge cell therapy R&D, reaching a consensus on future strategic clinical collaboration. They agreed to fully integrate the complementary strengths of medical and industrial partners, focusing on breakthroughs in cell therapy innovation and the translation of results, to jointly build a leading cell therapy industrial hub in Shenzhen and support the high-quality development of the biomedical industry in the Guangdong-Hong Kong-Macao Greater Bay Area.

Shenzhen Second People's Hospital (the First Affiliated Hospital of Shenzhen University) is one of the first triple-A tertiary general hospitals in Shenzhen and a Grade A+ institution in the national performance uation of tertiary public hospitals. It has established the Medical Innovation Technology Translation Center, which focuses on advancing the clinical translation of emerging biomedical technologies. The hospital possesses strong research capabilities and abundant clinical resources, and has recently set up the Shenzhen-Hong Kong Medical Innovation Technology Translation Center in the Hetao area, concentrating on cell and gene therapy and the clinical implementation of new technologies.